SCHEMBL14095985

SCHEMBL14095985

CCCCOC(=O)c1ccc(NC(=S)NC(=O)c2ccc(OC)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.64
POLB P06746 1/20 0.64
ALDH1A1 P00352 7/20 0.62
MAPT P10636 7/20 0.62
GAA P10253 2/20 0.62
CYP1A2 P05177 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
MAPK1 P28482 2/20 0.62
SMN1; SMN2 Q16637 4/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
HPGD P15428 1/20 0.60
RECQL P46063 1/20 0.60
LMNA P02545 1/20 0.59
SIRT2 Q8IXJ6 2/20 0.59
MEN1 O00255 2/20 0.57
HTT P42858 1/20 0.56
RNASEL Q05823 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14095980 0.89 ALDH1A1 (0.64) KMT2AALDH1A1MAPTGAACYP1A2
SCHEMBL14095965 0.89 ALDH1A1 (0.63) POLBALDH1A1MAPTGAACYP1A2
SCHEMBL14137019 0.88 CYP1A2 (0.65) KMT2AALDH1A1MAPTGAACYP1A2
SCHEMBL14095976 0.87 ALDH1A1 (0.61) ALDH1A1MAPTGAACYP1A2CYP2C9
SCHEMBL4375509 0.87 MAPT (0.67) KMT2APOLBALDH1A1MAPTGAA
SCHEMBL13956729 0.85 MAPT (0.60) KMT2AALDH1A1MAPTGAACYP1A2
SCHEMBL16587385 0.85 ALDH1A1 (0.78) KMT2AALDH1A1MAPTGAACYP1A2
SCHEMBL2864417 0.84 NPC1 (0.63) KMT2APOLBALDH1A1MAPTGAA
SCHEMBL4361509 0.84 HPGD (0.75) KMT2APOLBALDH1A1MAPTGAA
SCHEMBL13956723 0.83 ALDH1A1 (0.67) KMT2AALDH1A1MAPTGAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv RNASE1, SARS1, EIF2AK2 KMT2A 4579/4885POLB 70/4885ALDH1A1 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.